BR112022023931A2 - Derivado de anticorpo nr1 anti-humano - Google Patents
Derivado de anticorpo nr1 anti-humanoInfo
- Publication number
- BR112022023931A2 BR112022023931A2 BR112022023931A BR112022023931A BR112022023931A2 BR 112022023931 A2 BR112022023931 A2 BR 112022023931A2 BR 112022023931 A BR112022023931 A BR 112022023931A BR 112022023931 A BR112022023931 A BR 112022023931A BR 112022023931 A2 BR112022023931 A2 BR 112022023931A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- human
- nmdar
- present
- patients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
DERIVADO DE ANTICORPO NR1 ANTI-HUMANO. A presente invenção aborda o problema de fornecer um novo agente terapêutico para o tratamento de pacientes com encefalite anti-NMDAR. Os pacientes com encefalite anti-NMDAR têm um anticorpo NR1 anti-humano patogênico que induz a internalização de NMDAR na superfície celular. Como resultado, a função NMDAR é enfraquecida no cérebro dos pacientes. Os presentes inventores descobriram que o anticorpo NR1 anti-humano de um braço de acordo com a presente invenção se liga a NR1 competitivamente com o anticorpo NR1 anti-humano patogênico e inibe a internalização de NMDAR pelo anticorpo NR1 anti-humano patogênico para, assim, exibir efeito terapêutico sobre encefalite anti-NMDAR. Consequentemente, a presente invenção fornece um anticorpo anti-NR1 humano de um braço, um polinucleotídeo que codifica o anticorpo, um vetor de expressão contendo o polinucleotídeo, uma célula hospedeira transformada pelo vetor de expressão, um método para produzir o anticorpo, uma composição farmacêutica compreendendo o anticorpo, uma utilização do anticorpo no fabrico da composição farmacêutica e um método para tratar a encefalite anti-NMDAR utilizando o anticorpo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020092105 | 2020-05-27 | ||
PCT/JP2021/019929 WO2021241616A1 (ja) | 2020-05-27 | 2021-05-26 | 抗ヒトnr1抗体誘導体 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022023931A2 true BR112022023931A2 (pt) | 2023-04-11 |
Family
ID=78744563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022023931A BR112022023931A2 (pt) | 2020-05-27 | 2021-05-26 | Derivado de anticorpo nr1 anti-humano |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230220070A1 (pt) |
EP (1) | EP4159859A1 (pt) |
JP (1) | JPWO2021241616A1 (pt) |
KR (1) | KR20230029671A (pt) |
CN (1) | CN116133684A (pt) |
AU (1) | AU2021281828A1 (pt) |
BR (1) | BR112022023931A2 (pt) |
CA (1) | CA3180470A1 (pt) |
IL (1) | IL298537A (pt) |
MX (1) | MX2022014856A (pt) |
WO (1) | WO2021241616A1 (pt) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1998050431A2 (en) | 1997-05-02 | 1998-11-12 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
EP2805972A1 (en) | 2013-05-21 | 2014-11-26 | PAION Deutschland GmbH | Novel antibody useful in neurological or neurodegenerative disorders |
JP2018535922A (ja) * | 2015-08-17 | 2018-12-06 | ドイチェス ツェントルム フュール ノイロデゲネラティフェ アークランクンゲン エー.ファウ.(デーツェットエンエー) | 抗N−メチル−D−アスパラギン酸(NMDA)受容体抗体の結合領域に結合する抗体または抗体フラグメントまたは非Ig足場 |
-
2021
- 2021-05-26 AU AU2021281828A patent/AU2021281828A1/en active Pending
- 2021-05-26 JP JP2022526603A patent/JPWO2021241616A1/ja active Pending
- 2021-05-26 EP EP21812316.4A patent/EP4159859A1/en active Pending
- 2021-05-26 KR KR1020227045463A patent/KR20230029671A/ko unknown
- 2021-05-26 BR BR112022023931A patent/BR112022023931A2/pt unknown
- 2021-05-26 MX MX2022014856A patent/MX2022014856A/es unknown
- 2021-05-26 WO PCT/JP2021/019929 patent/WO2021241616A1/ja unknown
- 2021-05-26 CA CA3180470A patent/CA3180470A1/en active Pending
- 2021-05-26 IL IL298537A patent/IL298537A/en unknown
- 2021-05-26 CN CN202180058596.9A patent/CN116133684A/zh active Pending
-
2022
- 2022-11-17 US US18/056,635 patent/US20230220070A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021241616A1 (ja) | 2021-12-02 |
IL298537A (en) | 2023-01-01 |
AU2021281828A1 (en) | 2023-02-02 |
US20230220070A1 (en) | 2023-07-13 |
KR20230029671A (ko) | 2023-03-03 |
CA3180470A1 (en) | 2021-12-02 |
CN116133684A (zh) | 2023-05-16 |
JPWO2021241616A1 (pt) | 2021-12-02 |
EP4159859A1 (en) | 2023-04-05 |
MX2022014856A (es) | 2023-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019005133A2 (pt) | composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente sofrendo ou susceptível de sofrer de um distúrbio respiratório, para melhorar a estabilidade de uma composição farmacêutica, para melhoria do desempenho de dispersão em aerossol de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica. | |
BRPI0810118A8 (pt) | Método para tratar doença, método para efetuar profilaxia contra caa, uso de um agente, método para reduzir amilóide vascular em um paciente, e, kit para tratamento | |
BR112020019875A8 (pt) | composições tópicas para alívio da dor | |
Kuloglu et al. | Venlafaxine-associated nocturnal bruxism in a depressive patient successfully treated with buspirone | |
BR112021020106A2 (pt) | Moduladores da via de resposta ao estresse inte-grado | |
BR112022022578A2 (pt) | Novas composições e métodos de tratar doença covid-19 | |
BRPI0409742A (pt) | uso de um agente anti-angiogênico, em combinação com um inibidor da famìlia src de tirosina quinases não-receptoras, produto de combinação, e, composição farmacêutica | |
ZA202210355B (en) | Compositions and therapeutic uses of cannabidiol | |
BR0109672A (pt) | Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente | |
BR112021018506A2 (pt) | Terapia de combinação para tratamento do câncer | |
BR112022000957A2 (pt) | Uso de progestógeno para inibir tempestade de citocina e composição compreendendo progestógeno | |
BR112021019903A2 (pt) | Composição farmacêutica aquosa, uso da composição farmacêutica aquosa e método de produção de uma composição farmacêutica aquosa | |
BR112022000914A2 (pt) | Composição farmacêutica | |
BRPI0411665A (pt) | uso de agomelatina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica ou kit, e, métodos para o tratamento de doenças ou distúrbios responsivos a um inibidor da recaptação de serotonina e para aumentar e/ou proporcionar inìcio mais rápido do efeito terapêutico de um inibidor da recaptação de serotonina | |
BR112022023931A2 (pt) | Derivado de anticorpo nr1 anti-humano | |
BR112022015046A2 (pt) | Uso de forsitina e/ou seus derivados, método para a inibição da proteína 3clpro do vírus covid-19, uso de composição de forsitina/forsitosídeo, métodos para uso contra o vírus covid-19 ou para o tratamento de doenças causadas pelo vírus covid-19, composição de forsitina/forsitosídeo e medicamento compreendendo uma composição de forsitina/forsitosídeo | |
BR112021024233A2 (pt) | Implante para fixar um tendão ou um ligamento a um tecido duro compreendendo um eixo, primeiros pilares para entrar em contato com um tecido duro, e segundos pilares para entrar em contato com um tendão ou um ligamento | |
BR112021025558A2 (pt) | Formulação estável de cetrorelix e processo para a preparação de uma formulação estável | |
BR112022020882A2 (pt) | Tratamento da hidradenite supurativa | |
CL2021003312A1 (es) | Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma. | |
BR112023020538A2 (pt) | Derivados heterocíclicos, composições farmacêuticas e seus usos no tratamento ou na melhoria de câncer | |
BR0314651A (pt) | Composição farmacêutica, e, método para tratar infecção pelo hvi | |
BR112022000218A2 (pt) | Composição farmacêutica estável livre de lactose e processo para a preparação de uma composição farmacêutica estável livre de lactose | |
BR112022023176A2 (pt) | Composição que compreende hp hmg para uso no tratamento de infertilidade | |
BR112022014925A8 (pt) | Inibidores macrocíclicos de rip2-quinase |